39P Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: A phase Ib study in patients with advanced gastric cancer (RPT835GC1B)
Titel:
39P Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: A phase Ib study in patients with advanced gastric cancer (RPT835GC1B)
Auteur:
Tsimafeyeu, I. Kazey, V. Dragun, N. Reznikov, D. Gavrilova, E. Gorbacheva, S. Nikiforova, A. Byakhov, M. Tjulandin, S.